Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients.